Explore the multiple, distinct anticancer mechanisms of TTFields

The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells1-5

Select a mechanism to learn more about its function

Disruption of Mitosis
 

Interference with cell movement and migration

Enhancement of antitumor immunity

Downregulation of DNA damage response

TTFields therapy is clinically versatile, rooted in its multifaceted effects on cancer cells1-3

See how TTFields harness physics to disrupt mitosis

References: 1. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984 2. Voloshin T, Schneiderman RS, Volodin A, et al. Tumor treating fields (TTFields) hinder cancer cell motility through regulation of microtubule and actin dynamics. Cancers (Basel). 2020;12(10):1-18. doi:10.3390/cancers12103016 3. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009;28(1-2):5-14. doi:10.1007/s10555-008-9166-3 4. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:1-16. doi:10.1038/srep18046 5. Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152-10157. doi:10.1073/pnas.0702916104

Novocure Websites

This website is intended for people seeking information on Novocure’s worldwide business.

 

On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals.

 

Patient images reflect the health status of the patients at the time each photo or video was taken.




All rights reserved.

MyLink, MyNovocure, Novocure, and Optune Gio are trademarks of Novocure GmbH.

All other trademarks, registered or unregistered, are the property of their respective owners.

GLB-NOV-0039 v6.0 August 2024